HIV/AIDS Clinical Trials - Join Paid Clinical Trials for HIV/AIDS

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : AIDS

Top of Directory » All Categories » by Illness » AIDS



  • Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients

    Conditions:   HIV-1 Infection;   Cancer;   Immunosuppression
    Intervention:   Other: serologic testing
    Sponsors:   Johann Wolfgang Goethe University;   HIVCENTER
    Recruiting - verified November 2009
  • Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

    Condition:   Sarcoma
    Interventions:   Drug: bortezomib;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
    Sponsors:   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults

    Conditions:   Tuberculosis;   HIV Infections
    Interventions:   Biological: AERAS-402;   Biological: Placebo Control
    Sponsors:   Aeras Global Tuberculosis Vaccine Foundation;   Crucell Holland BV
    Not yet recruiting - verified November 2009
  • Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya

    Condition:   HIV Infections
    Interventions:   Other: CARE+ Kenya brief computer risk assessment session;   Other: CARE+ Kenya computer counseling session
    Sponsors:   New York University;   Indiana University;   Moi University
    Not yet recruiting - verified November 2009
  • Appropriate Timing of HAART in Co-infected HIV/TB Patients

    Conditions:   HIV Infections;   Tuberculosis
    Intervention:   Drug: tenofovir, lamivudine, efavirenz
    Sponsors:   Bamrasnaradura Infectious Diseases Institute;   Mahidol University;   Thai Red Cross AIDS Research Centre
    Recruiting - verified November 2009
  • Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Drug: valproic acid;   Genetic: western blotting;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   Centro de Cancer del Hospital Auxilio Mutuo
    Recruiting - verified November 2009
  • A Spanish-Language Intervention to Enhance Routine HIV Patient Care Delivery [CARE+ Spanish]

    Condition:   HIV Infections
    Interventions:   Other: CARE+ Spanish computer counseling session;   Other: CARE+ Spanish brief computer risk assessment session
    Sponsors:   New York University;   St. Vincent's Medical Center
    Not yet recruiting - verified November 2009
  • Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients

    Conditions:   HIV-1 Adults Patients;   AIDS;   Triple Class Failure
    Interventions:   Drug: maraviroc;   Drug: Raltegravir;   Drug: Darunavir/ritonavir
    Sponsors:   The Huesped Foundation;   Pfizer
    Not yet recruiting - verified November 2009
  • Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals.

    Condition:   HIV Infections
    Interventions:   Drug: Efavirenz;   Drug: Efavirenz
    Sponsor:   The National Centre in HIV Epidemiology and Clinical Research
    Not yet recruiting - verified November 2009
  • Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects

    Conditions:   Hypertriglyceridemia;   HIV Infection
    Interventions:   Dietary Supplement: Lovaza;   Drug: fosamprenavir/ritonavir
    Sponsors:   Felizarta, Franco, M.D.;   GlaxoSmithKline
    Recruiting - verified November 2009
  • Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1

    Condition:   HIV-1 Infections
    Intervention:   Drug: BMS-663068 with or without ritonavir
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • Multi-Site Evaluation of Progressive Tinnitus Management

    Condition:   Tinnitus
    Interventions:   Procedure: Progressive Tinnitus Management;   Procedure: Usual Care
    Sponsor:   Department of Veterans Affairs
    Not yet recruiting - verified November 2009
  • Concentrations of Maraviroc in the Semen of HIV-Infected Men

    Condition:   Maraviroc Concentrations in Semen
    Intervention:   Other: Measuring semen samples
    Sponsor:   Canadian Immunodeficiency Research Collaborative
    Recruiting - verified November 2009
  • Study to Evaluate the Safety and Immunogenicity of Poly ICLC (Hiltonol) in Healthy Volunteers

    Condition:   Healthy Volunteers
    Intervention:   Drug: Hiltonol (poly ICLC)
    Sponsor:   Rockefeller University
    Recruiting - verified November 2009
  • Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4

    Conditions:   Liver Cirrhosis;   Hepatitis C Virus;   HIV Infection
    Intervention:   Drug: Pegylated interferon alfa-2a and Ribavirin
    Sponsor:   Sociedad Andaluza de Enfermedades Infecciosas
    Recruiting - verified October 2009
  • Varenicline vs Placebo for the Treatment of Methamphetamine Dependence

    Conditions:   Methamphetamine Dependence;   Substance Abuse;   Methamphetamine Abuse
    Interventions:   Drug: Varenicline;   Drug: Placebo
    Sponsors:   National Institute on Drug Abuse (NIDA);   University of California, Los Angeles
    Recruiting - verified November 2009
  • Study Comparing Reduction and Viral Safety of IFN Alfa-2b XL + Ribavirin Versus PEG IFN Alfa-2b + Ribavirin in Patients With Chronic Hepatitis C Genotype 1

    Condition:   Chronic Hepatitis C
    Interventions:   Drug: IFN alfa-2b XL 27 MUI + Ribavirin;   Drug: IFN alfa-2b XL 36 MUI + Ribavirin;   Drug: IFN peg alfa-2b 1.5 µg/kg + Ribavirin
    Sponsor:   French National Agency for Research on AIDS and Viral Hepatitis
    Not yet recruiting - verified November 2009
  • Screening Tools to Predict Treatment Outcome in Older Cancer Patients Who Are Undergoing Treatment

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: chemotherapy;   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: examination;   Procedure: management of therapy complications
    Sponsor:   Ziekenhuis Netwerk Antwerpen Middelheim
    Recruiting - verified October 2009
  • Pilot Study of Text Message Reminders to Improve HIV Medication Adherence in Botswana

    Condition:   HIV Infections
    Intervention:   Other: Cell phone text message
    Sponsor:   University of Pennsylvania
    Recruiting - verified October 2009
  • Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV

    Conditions:   HIV Infections;   H1N1 Influenza
    Interventions:   Biological: Arepanrix;   Biological: Arepanrix
    Sponsors:   University of British Columbia;   Canadian Institutes of Health Research (CIHR)
    Not yet recruiting - verified October 2009
  • Integrating Family Planning Services Into HIV Care and Treatment in Nyanza Province, Kenya

    Conditions:   Unintended Pregnancy;   HIV Infections
    Intervention:   Procedure: Integrated family planning/HIV care and treatment services
    Sponsors:   University of California, San Francisco;   Ibis Reproductive Health;   Kenya Medical Research Institute;   Tides Foundation
    Recruiting - verified October 2009
  • Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: ritonavir;   Other: laboratory biomarker analysis;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults

    Conditions:   Pneumococcal Vaccines;   HIV;   HIV Infections
    Intervention:   Biological: Prevenar and Pneumo23
    Sponsors:   Hospital Universitari Son Dureta;   Hospital Son Llatzer;   Fondo de Investigacion Sanitaria
    Recruiting - verified October 2009
  • TMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy Volunteers

    Condition:   HIV Infections
    Intervention:   Drug: TMC278; Omeprazole
    Sponsor:   Tibotec Pharmaceuticals, Ireland
    Not yet recruiting - verified November 2009
  • Artery Elasticity After Switch From Epzicom to Truvada

    Condition:   HIV Infections
    Intervention:   Drug: Tenofovir disoproxil
    Sponsor:   Minneapolis Medical Research Foundation
    Recruiting - verified October 2009
  • ADHEPTA Study: Adherence Questionnaire in Hepatitis C

    Conditions:   Hepatitis C, Chronic;   HIV Infection
    Intervention:   Other: Adherence questionnaire
    Sponsor:   IMS Health
    Recruiting - verified October 2009
  • Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial

    Condition:   Drug Addiction
    Interventions:   Behavioral: Treatment as Usual (TAU);   Behavioral: TAU + Long-Term Recovery Management
    Sponsors:   Wright State University;   National Institute on Drug Abuse (NIDA);   Maryhaven;   University of Arkansas
    Not yet recruiting - verified October 2009
  • Computerized Screening, Brief Intervention, and Referral to Treatment in Primary Care

    Condition:   Substance Use Disorder
    Interventions:   Behavioral: Computerized brief intervention;   Behavioral: Computerized health screening;   Behavioral: Computerized assessment;   Behavioral: Therapist-delivered motivational intervention
    Sponsors:   Virginia Commonwealth University;   National Institute on Drug Abuse (NIDA)
    Not yet recruiting - verified October 2009
  • Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons

    Conditions:   Influenza;   H1N1;   HIV;   Vaccine;   HIV Infections
    Intervention:  
    Sponsors:   Uniformed Services University of the Health Sciences;   Infectious Disease Clinical Research Program;   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting - verified October 2009
  • Neighborhood Alcohol & HIV Prevention in South African Townships (Philani)

    Conditions:   Fetal Alcohol Syndrome;   HIV;   Nutrition Disorders
    Intervention:   Behavioral: Philani Intervention Program
    Sponsor:   University of California, Los Angeles
    Recruiting - verified October 2009
  • The Women's HIV SeroIncidence Study (ISIS)

    Condition:   HIV Infections
    Intervention:  
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified June 2009
  • Randomised and Prospective Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens

    Condition:   HIV Infections
    Interventions:   Drug: Darunavir/ritonavir;   Drug: Lopinavir/ritonavir
    Sponsor:   Germans Trias i Pujol Hospital
    Not yet recruiting - verified October 2009
  • Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma

    Condition:   Melanoma (Skin)
    Interventions:   Biological: aldesleukin;   Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified July 2009
  • Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine

    Condition:   Hepatitis, Chronic
    Interventions:   Drug: Lamivudine;   Drug: Telbivudine
    Sponsor:   University Hospital, Basel, Switzerland
    Recruiting - verified October 2009
  • The Shang Ring: A Novel Male Circumcision Device for HIV Prevention

    Conditions:   Male Circumcision;   HIV Prevention;   HIV Infections
    Intervention:   Device: Shang Ring circumcision
    Sponsors:   Weill Medical College of Cornell University;   Engenderhealth
    Recruiting - verified October 2009
  • Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1

    Conditions:   HIV-1 Infection;   HIV Infections
    Interventions:   Drug: maraviroc;   Drug: darunavir;   Drug: ritonavir
    Sponsors:   Northwestern University;   Pfizer;   Tibotec, Inc
    Not yet recruiting - verified October 2009
  • Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

    Conditions:   HIV Infections;   H1N1 Influenza Virus
    Intervention:   Biological: Influenza A (H1N1) 2009 monovalent vaccine
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting - verified October 2009
  • Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Women

    Conditions:   Malaria;   HIV Infections
    Interventions:   Drug: Lopinavir/ritonavir;   Drug: Efavirenz;   Drug: Zidovudine;   Drug: Lamivudine
    Sponsors:   University of California, San Francisco;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Not yet recruiting - verified October 2009
  • H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

    Condition:   Influenza
    Intervention:   Biological: Inactivated Influenza H1N1 vaccine
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified October 2009
  • Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

    Conditions:   HIV Infections;   H1N1 Influenza Virus
    Intervention:   Biological: Influenza A (H1N1) monovalent vaccine
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified October 2009
  • Durability of Adherence in Self-Management of HIV (The DASH Study)

    Condition:   HIV Infections
    Intervention:   Behavioral: Modified client adherence profiling and intervention tailoring (CAP-IT)
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting - verified October 2009
  • Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV

    Condition:   HIV Infections
    Intervention:   Drug: Raltegravir
    Sponsor:   Germans Trias i Pujol Hospital
    Not yet recruiting - verified October 2009
  • Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection

    Conditions:   HIV Infections;   Hepatitis C Virus
    Interventions:   Drug: Nitazoxanide (NTZ);   Drug: Peginterferon alfa-2a (PEG-INF);   Drug: Ribavirin (RBV)
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting - verified October 2009
  • Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults

    Condition:   HIV Infections
    Interventions:   Biological: PENNVAX-B;   Biological: IL-12 DNA plasmids
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified August 2009
  • Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy

    Condition:   HIV Infections
    Interventions:   Biological: WT-gag-TCR modified T cells;   Biological: α/6-gag-TCR modified T cells;   Other: STI or Drug Holiday
    Sponsor:   University of Pennsylvania
    Not yet recruiting - verified November 2009
  • Study of Vitamin D Supplementation to Male HIV Sero-positive Patients

    Condition:   HIV Seropositive
    Interventions:   Drug: Rocaltrol;   Drug: Vitamin D;   Drug: Calcium
    Sponsor:   Hvidovre University Hospital
    Recruiting - verified October 2009
  • Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

    Conditions:   Immune Reconstitution Inflammatory Syndrome;   HIV;   HIV Infections
    Interventions:   Drug: maraviroc;   Drug: Placebo
    Sponsors:   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran;   University of Witwatersrand, South Africa;   Case Western Reserve University;   Wistar Institute;   University of Pennsylvania
    Not yet recruiting - verified October 2009
  • Europe-Africa Research Network for Evaluation of Second-line Therapy

    Conditions:   Human Immunodeficiency Virus;   HIV Infections
    Interventions:   Drug: Aluvia + 2NRTIs;   Drug: Aluvia + raltegravir;   Drug: Aluvia monotherapy
    Sponsors:   Medical Research Council;   European and Developing Countries Clinical Trials Partnership
    Not yet recruiting - verified September 2009
  • Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

    Condition:   HIV Infections
    Intervention:   Drug: maraviroc (Selzentry)
    Sponsors:   University of Hawaii;   Pfizer Pharmaceutical
    Not yet recruiting - verified September 2009
  • Effect of Rosuvastatin on Cardiovascular Risk in HIV-Infected Individuals With Low High Density Lipoprotein (HDL) Cholesterol

    Conditions:   HIV Infections;   Cardiovascular Disease
    Intervention:   Drug: rosuvastatin
    Sponsor:   University of Hawaii
    Not yet recruiting - verified September 2009
    • Menu
    Find Paid Clinical Trials